AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05776875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
Study NCT05776875 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization
Description: Transarterial chemoembolization (TACE) is a local therapy for HCC which induces tumor necrosis.
Study NCT04981002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine Consultation with self orthopedic exam
Description: Brief telemedicine consultation, with self orthopedic exam,blinded to subsequent face-to-face evaluation.
Study NCT04981002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face Consultation
Description: Direct face-to-face evaluation (without telemedicine consultation before).
Study NCT06026735 — intervention group
Intervention type: OTHER
Intervention: lung cancer with brain /leptomeningeal metastasis
Description: Cerebrospinal fluid was obtained from the cerebrospinal cavity of non-small cell lung cancer patients with central nervous system metastasis, blood was obtained from veins, and metastatic lung cancer tumor tissue was obtained from surgically resected brain tumors or meningeal tumors. Then comprehensively analyze the exosomes contained in the aforementioned samples, and compare and analyze the clinical data of the patients, so as to explore whether the cancer cell-related substances contained in the cerebrospinal fluid, blood and tumor tissue can be used to predict lung cancer metastasis and Bioindicators of treatment effect.
Study NCT06303401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SI joint thrust manipulation
Description: experimental group given the thrust manipulation along with heating pad. 3 sessions per week will be given for 4 weeks. The pain measure by using NPRS, functional status and disability through ODI will be evaluated.~after every 3 sessions.
Study NCT06303401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic stabilization exercises
Description: Heating pad for 10- 15 mints Pelvic stabilization exercises include Bridging (3 sets x 10 reps with 10 secs hold) Pelvic Tilt exercise(3 sets x 10 reps with 10 secs hold) Bird-Dog Exercise (3 sets x 10 reps with 10 secs hold) clamshell Exercise (3 sets x 10 reps with 10 secs hold) .3 sessions per week will be given for 4 weeks. The pain using NPRS , functional status and disability will be evaluated by using ODI after every 3 sessions.
Study NCT04699474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leg ergometer
Description: Leg cycling in bed using motorized ergometer
Study NCT05032027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotics
Description: recieving probiotics at the first day of chemoradiotherapy daily
Study NCT04996914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: 1-2 session TACE before SBRT according to the preference of the interventional radiologist. Goal of TACE is the complete emnbolization of the HCC-nodules. It is allowed to use both conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) according to the interventional radiologist preference.
Study NCT04996914 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT should be 1 month after last TACE. This can be extended till 2 months if indicated. However, prolongation of the gap between TACE and SBRT is not encouraged.~Treatment center should choose one of fractionation schedule mentioned allowed in the study, in order to achieve a balance between dose applied for tumor control and constraints for OAR PTV Dose in 5 / 8 fractions (Gy) BED (α/β 10Gy) 5x 10 Gy @ 83% isodose = 50 Gy (100 Gy) 8 x 7.5 Gy @ 83% isodose = 60 Gy (105 Gy)
Study NCT05084872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Patients will be treated by hydroxychloroquine at a dose of 6 to 6.5mg/kg/day during 12 month
Study NCT05404542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Oral tablets
Study NCT05238935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prescribed physiotherapy course
Description: provide full assessment and treatment program as postoperative rehabilitation management
Study NCT06340113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MCKENZIE AND STABILIZATION EXERCISES
Description: In this group 11 participants will receive McKenzie protocol with stabilization exercises. Participants will be asked to sit to treat extension deficit. The participant will be in a comfortable sitting position with a proper back support. Head is kept in forward facing without any up and done movement (10 to 15 times). Then, he restored the neutral sitting posture, and at the end of the range of motion (ROM), he' tuck in chin by pushing the chin with his fingers (10 to 15 times). The exercises then repeated five or six times in a Session. the session will be of 45 mins, 3 session per week. At end of each session patients will do stabilization exercises with 10reps of each exercise with 10sec hold
Study NCT06340113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MULLIGAN AND STABILIZATION EXERCISES
Description: . The technique will include Self-sustained Natural Apophyseal Glide (SNAGs), Natural Apophyseal Glides (NAGs), and mobilization techniques.. The participants will receive three sets of Mulligan Mobilization, each set involving 10 repetitions of the exercise, with an interval of 15 to 20 seconds between the sets.At end of each session patients will do stabilization exercises with 10reps of each exercise with 10sec hold.
Study NCT06222138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The samples described below will be collected:
Description: For each included patient, blood samples will be collected during baseline visit (before initiation of radio-chemotherapy), then before initiation of TTFields and every 3 months during TTFields treatment. Additional blood samples will be scheduled at recurrence (if applicable).~Moreover, tumor samples (formalin paraffin embedded (FFPE) tumor block and fresh samples) will be collected from surgery specimen on primary tumor by the sponsor for analysis. In case of recurrence, and if a second surgery is possible, tumor samples will also be collected.~Tumor samples will be collected from biopsies taken in the course of routine practice and from surgical specimens collected during surgical procedure.
Study NCT05585723 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires completion
Description: Prospective, qualitative, observational, single-center study. 1) Two independent translations of the original questionnaires into French, 2) Back-translation of the consensus version into English by a professional bilingual translator 3) We will submit this final version to two opinion leaders in France. 4) Evaluation of the clarity, comprehension and acceptability of the translation of the questionnaire.
Study NCT05887193 — intervention group
Intervention type: DEVICE
Intervention: Biothesiometry
Description: Biothesiometry using Biothesiometer (Bio Medical Instrument Co, Ohio, United States of America), placed on glans penis and second finger of nondominant hand.
Study NCT06343415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GAIT-assisted training
Description: GAIT duration starts when walking is started. The participant will walk as intensively as possible within prespecified safety limits. Intensity is considered the most important factor for the feasibility outcome of the completion ratio and for the safety outcomes. Intensity encompasses duration and repetitions.~Duration: 10 minutes is considered the minimum acceptable duration for a session to be deemed complete and 30 minutes as the maximum duration for a training session.~Repetitions: A step intensity of approximately 1000 steps per session is considered as high intensity and training aims to reach this amount. This is based on neuroplasticity theories. Speed starts at 1 km/h and is adjusted accordingly.~The body weight support (BWS) is kept between 60-100% of total body weight. The BWS is adjusted so the knee flexion in the stance phase does not exceed 10 degrees. The guidance force is kept at 100% and symmetric in all sessions.
Study NCT06343415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STEP-assisted training
Description: STEP duration starts when stepping and elevation are started. The participant will step as intensively as possible within prespecified safety limits. Intensity is considered the most important factor for the feasibility outcome of the completion ratio and for the safety outcomes. Intensity encompasses duration and repetitions.~Duration: 10 minutes is considered the minimum acceptable duration for a session to be deemed complete and 30 minutes as the maximum duration for a training session.~Repetitions: A step intensity of approximately 1000 steps per session is considered as high intensity and training aims to reach this amount. This is based on neuroplasticity theories. Step cadence starts at 40 steps/minute and cadence is adjusted accordingly.~The leg loading starts a 5 kg and is, if possible, increased to a maximum of 40% of total body weight while adjusting knee extension to ≤10 degrees flexion in stance. The guidance force is kept at 100% and symmetric in all sessions.
Study NCT05643742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX112
Description: CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
Study NCT05560568 — intervention group
Intervention type: OTHER
Intervention: Sleep parameters data collection
Description: Sleep parameters collected before and after hybrid close-loop pump activation. Data collected with adequate devices (i.e. actigraph and Dreem Band).
Study NCT05887193 — intervention group
Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: Penile oxygen pressure using TCM5 Flex and tc84 electrode (Radiometer Medical ApS, Brønshøj, Denmark) placed on glans penis.
Study NCT05887193 — intervention group
Intervention type: DEVICE
Intervention: Cycling on a home trainer
Description: Riding a static bike Wahoo Bike (Wahoo Fitness LLC, Atlanta, Georgia, United States of America) for 3x 10 minutes at 65-85% of each individual subjects maximal heart rate.
Study NCT05532111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab combined with tacrolimus induction + rituximab maintenance
Description: RT-R group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml). At the end of 24 weeks, tacrolimus was stopped, and rituximab was given 1 g/time × 1 time.
Study NCT05532111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab combined with tacrolimus induction + tacrolimus maintenance
Description: RT-T group: Rituximab 1 g/time, once in 15 days, × 2 times, combined with tacrolimus, the initial dose is 0.05-0.1 mg/kg/d, 2 times at an interval of 12 hours, orally. Adjust the dose according to the blood concentration (maintain the blood concentration C0 4-8ng/ml).
Study NCT05532111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid combined with cyclophosphamide induction + maintenance
Description: PC-C group: The initial dose of prednisone/prednisolone was 0.5-1 mg/kg/d (the maximum dose was 70 mg/d), and the dose was gradually reduced after 4-8 weeks, and then stopped within 6-9 months. Cyclophosphamide 750mg/m2 (adjusted according to eGFR and other conditions), once a month, intravenous pulse therapy. CTX maintenance therapy.
Study NCT06313606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fat negative control
Description: Dietary fat-containing meal plan with a specific supplement that should not modify fat metabolism
Study NCT06010368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: In TXA group (n=75): 1 g from tranexamic acid (kapron®, Amoun, Egypt) shall also be watered down in 10 cc of Saline, and 5 cc shall be injected in each uterine corn before the placenta is separated.
Study NCT06010368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: the oxytocin group (n = 75): 5 I.U of oxytocin (syntocinone 5 I.U/1ML NONARTIS-EGYPT) shall be watered down in 10 cc of saline, and 5 cc shall be injected into each uterine corn before the placental separation
Study NCT06492057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS)
Description: EasymotionSkin body suit for digitally controlled electric impulses via Easymotion-2 software on crew iPad (frequency, impulse rate, duration) are transferred from integrated dry electrodes of the EMS- stimulation suit to activate surface muscle groups of the body (trunk), arms and legs
Study NCT06492057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myoton
Description: The non-invasive Myoton technology collects data from passive muscle properties (tone and stiffness) obtained from selected anatomical surface muscle groups
Study NCT06041581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using The Internet (SHUTi)
Description: Sleep Healthy Using The Internet (SHUTi) is an empirically supported internet intervention. It uses a fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. Each session has the same structure: objectives, sleep diary and homework review, new intervention material, homework assignment, and summary. SHUTi is enhanced through interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program. We provide basic tablet skills training and tablets with data plans when needed.
Study NCT06041581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic CBT-I
Description: Telephonic CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Telephonic CBT-I will be delivered from a central location - the Insomnia Clinical Specialist's office. Telephonic CBT-I has been shown to be acceptable, feasible, and effective, with effect sizes similar to face-to-face CBT-I.
Study NCT06041581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face CBT-I
Description: Face-to-face CBT-I will be delivered by our insomnia clinical specialist following the highly cited treatment manual by Perlis et al. (2005). Sessions will occur weekly for 30-50 minutes. Face-to-face CBT-I will be delivered at the Insomnia Clinical Specialist's office. CBT-I is the clear first-line treatment for insomnia.
Study NCT06041581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control: Sleep Education/Hygiene, Symptom Monitoring, and Usual Primary Care
Description: A designated trial research assistant will have two calls with each AC patient - one 45-minute call on insomnia education and one 45-minute call on sleep hygiene practices. The same research assistant will also call AC patients monthly to assess insomnia symptoms and will notify clinical staff to encourage additional care when indicated. AC patients will receive usual primary care for insomnia. The targeted clinics utilize a team care approach for behavioral health issues, as PCPs are supported by behavioral health clinicians and psychiatrists available for brief counseling and medication management. However, there is no routine screening for insomnia, and behavioral treatment for insomnia is typically limited to sleep hygiene practices.
Study NCT06547723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBSR and physiotherapy
Description: In experimental group in the first session, the research program and plans for outcome assessment will be introduced. They will sign the research agreement form and will be interviewed to obtain information about their pain, their medication(s), and demographics. This will be followed by the first 70-80-minute physiotherapy session. During each session, the physiotherapist will administer the Transcutaneous electrical nerve stimulation (TENS), low-level laser therapy (LLLT), and ultrasound therapy to the painful body region. In addition, they will engage in 20 minutes of exercise during each session.~After that, participants will be received their 8 MBSR session with a trained therapist. They will be given their assignments for the week, consisting of the content of that MBSR session.~Finally, three months after the last study session, they will be asked to return to the clinic for the follow-up assessment to complete patient-reported outcome measures.
Study NCT06547723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: In control group in the first session, the research program and plans for outcome assessment will be introduced. The participants then will sign the research agreement form and will be interviewed to obtain information about their pain (i.e., duration, location, and course), their medication(s), and demographics. This will be followed by the first 70-80-minute physiotherapy session. During each session, the physiotherapist will administer the Transcutaneous electrical nerve stimulation (TENS), low-level laser therapy (LLLT), and ultrasound therapy to the painful body region. In addition, they will engage in 20 minutes of exercise during each session.
Study NCT05258318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DK crush
Description: Double Kissing Crush (DK-Crush) technique in patients with Unprotected Left Main Bifurcation lesions (ULMb).
Study NCT05258318 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DR crush
Description: Double Rewire crush technique (DR-Crush) in patients with Unprotected Left Main Bifurcation lesions (ULMb).
Study NCT00511745 — intervention group
Intervention type: DRUG
Intervention: Rabeprazol
Description: As prescribed
Study NCT05727267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV B; TherVacB
Description: Administration of the described combinations via the intramuscular route
Study NCT05727267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB
Description: Administration of the described combinations via the intramuscular route
Study NCT05887193 — intervention group
Intervention type: DEVICE
Intervention: Bike Fitting
Description: Setting standardized posture of the rider on the bike using Retül technology (Retül, Specialized Bicycle Components Inc., Boulder, Colorado, United States of America)
Study NCT06022315 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: caloric restrction high carbohydrate low fat diet with exercise training program
Description: Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold. The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the high CHO-low FAT diet, carbohydrates, fat, and protein will provide 60%, 25%, and 15% of individually predicted daily energy intake, respectively. Variety (n=7) of daily menus for calorie-restricted high FAT-low CHO diet will be provided and menus for high CHO-low FAT diet on pasta, rice, oats, fruit, and vegetable.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week.
Study NCT06022315 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: caloric restrction high fat low carbohydrate diet with exercise training program
Description: Subjects will perform 3 sessions/week of brisk walking for four weeks at a heart rate corresponding to 85-90% of the lactate threshold.The duration of exercise sessions will increase from 30 minutes to 45 minutes in week 2 and from 45 minutes to 60 minutes in weeks 3 and 4.~Experimental diets will be calorie-restricted and provide 70% of estimated daily energy requirements. In the low CHO-high FAT diet, the proportion of energy provided by CHO, fat, and protein will consist of 25%, 60%, and 15%, respectively. Variety (n=7) of daily menus for calorie-restricted low CHO-high FAT diet will be provided and menus for high FAT-low CHO group will be based on meat, fish, cheese, butter, and nuts.During the intervention, participants will be encouraged to avoid alcohol consumption and only the maximum amount of two units will be allowed per week.
Study NCT04976010 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention in the separate goups, as this is an observational study
Study NCT05923801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: switch to BT electrode position
Description: use of different electrode positions of ECT device
Study NCT05923801 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continue with RUL electrode position
Description: use of different electrode positions of ECT device
Study NCT05891093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib 50mg bid orally for 1 year.
Study NCT05891093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg, qd orally
Study NCT05891093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg, qd orally
Study NCT05891093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5mg, qd orally
Study NCT05891093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg, qd orally